The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function

British Journal of Clinical Pharmacology

Volumn 49, Issue SUPPL. 1, 2000, Pages 27-33

  Aweeka, F ^a   Jayesekara, D ^a   Horton, M ^b   Swan, S ^c   Lambrecht, L ^c   Wilner, K D ^d   Sherwood, J ^d   Anziano, R J ^d   Smolarek, T A ^d   Turncliff, R Z ^d  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b Center for Clinical Research   (United States)

^c Drug Evaluation Unit   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Haemodialysis; Pharmacokinetics; Renal impairment; Ziprasidone

Indexed keywords

ZIPRASIDONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MULTICENTER STUDY; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0034061639     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00150.x     Document Type: Article

References (10)

1. Prakash C, Kamel A, Cui D, et al. Identification of the major human liver cytochrome P450 isoform responsible for the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49(Suppl. 1): 35S-42S.
2. Wilner KD, Tensfeldt TG, Baris B, et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 2000; 49(Suppl. 1): 15S-20S.
3. Morrison RBI, Davidson JM, Kerr DNS. Clinical physiology of the kidney. Tests of renal function and structure. In Oxford Textbook of Medicine, 2nd edn, eds Weatherall DJ, Ledingham JGG, Warrell DA. Oxford University Press, 1989, 18.2-18.17.
4. Janiszewski JS, Fouda HG, Cole RO. Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase excavation and narrow-bore high-performance liquid chromatography. J Chromatogr 1995; 668: 133-139.
5. Boudinot FD, Jusko WJ. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 1984; 6: 774-780.
6. 1-acid glycoprotein: implications for binding of drugs. Ther Drug Monit 1986; 8: 259-293.
7. 2 receptors by the neuroleptic ziprasidone (CP-88, 059, 01) determined by positron emission tomography. Psychopharmacology 1996; 124: 141-147.
8. Howard HR, Prakash C, Seeger TF. Ziprasidone hydrochloride. Drugs Future 1994; 19: 560-563.
9. De Vane CL. Brief comparison of the pharmacokinetics and pharmacodynamics of the traditional and newer antipsychotic drugs. Am J Health Syst Pharm 1995; 52(Suppl 1): S15-S18.
10. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995; 122: 223-229.